Eosinophilic Cellulitis Pathogenesis May Involve JAK1/JAK2-STAT5 Pathways Doug Brunk June 26, 2023 0 ...

New data were recently published showing that SHR0302, better known as ivarmacitinib, is safe and effective to use in adolescent and adult patients against atopic dermatitis, the most common ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Q: What was your most unexpected finding? The most unexpected finding in our study is that JAK1/2, two essential kinases in the IFN-g signaling cascade, are actually activated rather than suppressed ...

Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated ...

As a brain-penetrant, selective inhibitor of TYK2 and JAK1, BHV-8000 has the potential to modulate critical inflammatory pathways, in the periphery and in the CNS, that results in neuronal loss ...

As a brain-penetrant, selective inhibitor of TYK2 and JAK1, BHV-8000 has the potential to modulate critical inflammatory pathways, in the periphery and in the CNS, that results in neuronal loss ...